Senolytics for Men Over 40: What Fisetin, Quercetin and Dasatinib Actually Do to Senescent Cells

Senolytics are drugs and plant compounds that selectively kill senescent cells, the damaged cells that stop dividing but refuse to die and leak inflammatory signals into surrounding tissue. In old mice, intermittent senolytic doses improved walking speed, grip strength and remaining lifespan. Human trials of dasatinib plus quercetin and of fisetin are small and mixed. This guide covers the data, the dosing used in trials and the real risks.

Senolytics are compounds that selectively kill senescent cells, the damaged cells that have stopped dividing but do not die off the way they should. Senescent cells are often called zombie cells because they linger in tissue and release a mix of inflammatory proteins known as the senescence-associated secretory phenotype, or SASP. Senescent cells accumulate with age in fat, muscle, blood vessels, joints and the immune system, and the SASP they release is one driver of the low-grade chronic inflammation researchers call inflammaging.

The senolytic idea is simple. If a small number of senescent cells cause a disproportionate amount of damage, then clearing them every few weeks might slow parts of aging. The three senolytics men hear about most are fisetin, a flavonoid found in strawberries; quercetin, a flavonoid found in onions and apples; and dasatinib, a prescription leukemia drug. The mouse results are striking. The human results are much smaller and far less certain, and the gap between the two matters for any man over 40 weighing a senolytic protocol.

Senescent cells are cells that have permanently stopped dividing in response to damage such as DNA breaks, shortened telomeres, oxidative stress or oncogene activation. Senescence is protective at first, because a damaged cell that stops dividing cannot become a tumor. In a young body, the immune system clears senescent cells quickly. With age, senescent cells are produced faster and cleared more slowly, so the number of senescent cells in tissue climbs steadily after midlife.

A common marker of senescence is p16INK4a, a protein that halts the cell cycle. Research by Norman Sharpless and colleagues, published in Aging Cell in 2009, found that p16INK4a expression in human T cells rises steadily with age, and that smoking and physical inactivity push it higher. The chart below shows the general pattern of senescent cell burden across adulthood. The values are illustrative, not measurements from a single study.

Senescent cells matter out of proportion to their numbers because the SASP spreads the damage. SASP proteins include interleukin 6, interleukin 8, TNF alpha and enzymes that break down tissue scaffolding. These signals can push nearby healthy cells into senescence, blunt muscle repair, stiffen blood vessels and interfere with insulin signaling in fat tissue. Visceral fat in overweight men is one of the richest sources of senescent cells in the body.

In animal studies, clearing senescent cells improved physical function and extended lifespan. Darren Baker, Jan van Deursen and colleagues at the Mayo Clinic showed in Nature in 2016 that genetically removing p16-positive cells from naturally aging mice extended median lifespan by roughly 17 to 35 percent and delayed kidney and heart decline. That study used a genetic switch, not a drug, but it established that senescent cells cause harm rather than simply marking age.

The drug studies followed. Ming Xu, James Kirkland and colleagues reported in Nature Medicine in 2018 that transplanting a small number of senescent cells into young mice was enough to cause measurable weakness and slower walking. The same paper showed that giving very old mice dasatinib plus quercetin once every two weeks improved walking speed, grip strength and endurance, and increased remaining lifespan by about 36 percent. Matthew Yousefzadeh and colleagues then screened 10 flavonoids in EBioMedicine in 2018 and found fisetin was the most potent senolytic of the group, extending median and maximum lifespan in mice by roughly 10 percent when added to the diet late in life.

Human senolytic trials show that dasatinib plus quercetin can reduce senescent cell markers in people, but clinical benefits have been small, inconsistent or limited to subgroups. Most published trials enrolled fewer than 60 people, ran for weeks rather than years, and studied patients with a specific disease rather than healthy men in midlife.

The first human senolytic trial, led by Jamie Justice and published in EBioMedicine in 2019, gave 14 patients with idiopathic pulmonary fibrosis dasatinib 100 mg plus quercetin 1,250 mg on three days a week for three weeks. Walking distance, gait speed and chair-stand time improved, but lung function did not change and there was no placebo group. A second 2019 study by LaTonya Hickson gave nine patients with diabetic kidney disease dasatinib 100 mg plus quercetin 1,000 mg for three days. Eleven days later, biopsies showed fewer senescent cells in abdominal fat and lower levels of several SASP proteins in blood.

The largest randomized trial so far, led by Joshua Farr and Sundeep Khosla at the Mayo Clinic and published in Nature Medicine in 2024, tested dasatinib plus quercetin in 60 postmenopausal women. Doses were given on two consecutive days every four weeks for 20 weeks. The primary outcome, a blood marker of bone breakdown, did not change significantly compared with control. Women with the highest senescent cell burden at the start did show improved bone density at the wrist, which suggests senolytics may help only people who carry a large senescent load.

The osteoarthritis failure is worth knowing. Unity Biotechnology's UBX0101, a senolytic injected directly into arthritic knees, did no better than placebo for pain in a 2020 phase 2 trial. That result did not disprove the senolytic theory, but it showed that clearing senescent cells does not automatically translate into symptoms people can feel.

Fisetin as a senolytic is dosed intermittently at high levels, not daily at low levels. The Mayo Clinic fisetin trials use 20 mg per kilogram of body weight taken on two consecutive days, repeated about once a month. For a 70 kg (154 lb) man that works out to about 1,400 mg per day on the two dosing days. The logic is hit-and-run: senescent cells take weeks to build back up, so a short burst can clear them without constant exposure.

Fisetin is poorly absorbed on its own, and most fisetin supplements sold at 100 mg daily deliver a fraction of what the trials use. Some products pair fisetin with fats or phospholipids to improve absorption, but no head-to-head human data shows which form reaches senescent cells best. Food cannot supply a senolytic dose. Strawberries are the richest common source at about 160 micrograms of fisetin per gram, according to a 2000 analysis by Yukiko Arai and colleagues, so a 70 kg man would need roughly 9 kg of strawberries to match one trial dose.

Quercetin alone is a weak senolytic. In the original 2015 Aging Cell screen by Yi Zhu and James Kirkland, quercetin killed senescent human endothelial cells but was much less effective against senescent fat precursor cells, which is why it was paired with dasatinib. Dasatinib and quercetin target different survival pathways, so the combination covers more senescent cell types than either one alone. Quercetin taken daily at 500 to 1,000 mg may have modest anti-inflammatory effects, but that is a different use from intermittent senolytic dosing.

Dasatinib is not considered safe for healthy men to take on their own. Dasatinib is a prescription tyrosine kinase inhibitor approved for chronic myeloid leukemia, where patients take 100 mg daily for years under close monitoring. Known risks include low blood counts, bleeding, fluid buildup around the lungs, pulmonary hypertension and heart rhythm changes. Short intermittent senolytic courses have been reasonably well tolerated in trials, but those trials screened participants carefully and tracked blood counts, and any use outside a trial belongs under a physician's supervision.

Senolytics have not been shown to affect testosterone in men. Rodent studies show that Leydig cells, the testosterone-producing cells in the testes, develop senescence markers with age, and a few mouse studies suggest clearing senescent cells can partly restore testicular function. No published human trial has measured testosterone as an outcome of senolytic treatment.

The indirect link is more plausible. Senescent cells in visceral fat drive insulin resistance and inflammation, and both are tied to lower testosterone in men over 40. Losing visceral fat, training regularly and keeping blood sugar in check reduce senescent cell burden and support healthy testosterone at the same time. A 2021 study in Aging Cell by Davis Englund and colleagues found that a 12 week exercise program lowered circulating markers of senescence in older adults, which puts exercise on the same list as the experimental compounds.

A man over 40 can approach senolytics sensibly by fixing the lifestyle drivers of senescence first, getting baseline blood work, and treating any fisetin protocol as a supervised experiment with clear measurements. The framework below is educational and mirrors the structure of published trials. It is not medical advice.

• Taking 100 mg of fisetin daily and assuming it matches trial protocols that used 1,000 mg or more on two days a month
• Buying dasatinib from research chemical sites, which bypasses the blood count monitoring used in every trial
• Stacking several senolytics at once, which raises interaction risk and makes effects impossible to read
• Expecting symptom changes within days, when trial benefits were measured over weeks to months
• Ignoring visceral fat, inactivity and smoking, which keep producing new senescent cells

Continue Reading

Related Articles

Longevity

Urolithin A for Men Over 40: What the Mitophagy Trials Actually Show About Muscle, Energy and Aging

10 min read

Read Article →

Lab Markers

hs-CRP in Men Over 40: The Inflammation Marker Most Blood Panels Leave Off

11 min read

Read Article →

Longevity

Rapamycin: What Men Over 50 Should Know About the Longevity Drug

13 min read

Read Article →